The accurate diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) remains a clinical challenge, primarily relying on invasive liver biopsy to confirm inflammation and fibrosis. New data presented at EASL Congress 2026 suggests that a panel of non-invasive biomarkers could significantly reduce the need for biopsy in specific patient populations, streamlining diagnostic pathways.
- The Pivot Non-invasive biomarker panels are demonstrating sufficient accuracy to potentially defer or replace liver biopsy for MASH diagnosis in certain contexts.
- The Data A composite score achieved a negative predictive value of 92% for advanced fibrosis (F3-F4) and a positive predictive value of 78% for MASH activity score ≥4.
- The Action Clinicians should consider incorporating validated non-invasive scores into their MASH diagnostic algorithms, particularly for screening and monitoring, while awaiting further validation for definitive diagnosis.
MASH, previously known as non-alcoholic steatohepatitis (NASH), is characterised by hepatic steatosis, inflammation, and hepatocyte ballooning, often progressing to fibrosis and cirrhosis.1 The current gold standard for diagnosis and staging of MASH is liver biopsy, which carries risks including pain, bleeding, and, rarely, mortality.2 Furthermore, biopsy is subject to sampling variability and inter-observer differences in histological interpretation.3 The need for less invasive, more accessible diagnostic tools is substantial, particularly given the rising global prevalence of MASH.4
What the Liver Could Have Told Us Sooner
At EASL Congress 2026, researchers presented findings from a multicentre prospective study (N=2,850) evaluating the diagnostic performance of a novel panel of serum biomarkers for MASH and advanced fibrosis. The study enrolled adults with suspected MASH, defined by metabolic risk factors and imaging evidence of hepatic steatosis. All participants underwent a liver biopsy, which served as the reference standard. The biomarker panel included established markers such as AST, ALT, platelet count, albumin, and novel proteomic and metabolomic markers.5
The primary endpoint was the diagnostic accuracy of the biomarker panel for MASH (defined as NAFLD Activity Score (NAS) ≥4 with inflammation and ballooning) and for advanced fibrosis (F3-F4) as per the MASH Clinical Research Network scoring system. Secondary endpoints included correlation with histological features and prediction of clinical outcomes over a 2-year follow-up period.5
The study demonstrated that the composite biomarker score achieved an area under the receiver operating characteristic curve (AUROC) of 0.87 (95% CI 0.85-0.89) for the diagnosis of MASH and an AUROC of 0.91 (95% CI 0.89-0.93) for advanced fibrosis. For advanced fibrosis (F3-F4), a predefined cut-off yielded a sensitivity of 85% and a specificity of 88%, with a negative predictive value (NPV) of 92% and a positive predictive value (PPV) of 78%. For MASH activity score ≥4, the sensitivity was 79%, specificity 82%, NPV 88%, and PPV 70%. The p-value for all primary and secondary endpoints was <0.001.6
These results indicate that the non-invasive panel could effectively rule out advanced fibrosis in a significant proportion of patients, potentially reducing the number of biopsies required. The panel also showed a strong correlation with histological inflammation and ballooning, suggesting its utility in identifying active MASH. During the 2-year follow-up, patients classified as high-risk by the non-invasive panel had a significantly higher incidence of liver-related events (HR 2.87, 95% CI 2.15-3.83; p<0.001) compared to those classified as low-risk.6
While promising, the study acknowledged limitations, including the need for external validation in diverse populations and the fact that the PPV for MASH diagnosis, while substantial, still leaves a proportion of patients requiring biopsy for definitive confirmation. The study population was predominantly of European descent, and further research is needed to assess the panel's performance in other ethnic groups. The cost-effectiveness of integrating this panel into routine clinical practice also warrants further investigation. Future research will focus on refining the panel and exploring its role in monitoring treatment response.7
The data from EASL 2026 on non-invasive MASH diagnostics offers a tangible step towards reducing the reliance on liver biopsy. For general practitioners and specialists managing patients with metabolic syndrome, the prospect of a highly accurate negative predictive value for advanced fibrosis means fewer patients will need to undergo an invasive procedure. This is not merely a comfort factor; it translates to reduced healthcare costs, fewer procedure-related complications, and a more efficient diagnostic pathway for a condition with a rapidly expanding patient base. The challenge now lies in integrating these validated panels into clinical guidelines, ensuring that clinicians are equipped to interpret and act upon these scores appropriately.
The pharmaceutical industry, heavily invested in MASH therapeutics, will undoubtedly welcome these advancements. A more accessible and less burdensome diagnostic process could significantly broaden the pool of patients identified for potential treatment, accelerating recruitment for clinical trials and facilitating earlier intervention once therapies are approved. Companies developing MASH drugs, such as Madrigal Pharmaceuticals with resmetirom, or those with pipeline candidates, will benefit from a clearer, faster path to patient identification. However, the moderate positive predictive value for MASH activity itself suggests that biopsy will retain its role for definitive diagnosis in a subset of patients, particularly those with equivocal non-invasive results or where precise staging is critical for therapeutic decisions.
From a patient perspective, this represents a substantial improvement in their diagnostic journey. The anxiety and discomfort associated with liver biopsy are considerable, and any validated method that can reduce its necessity is a significant win. While the panel may not entirely eliminate the need for biopsy, it offers a triage mechanism that can spare many from an invasive procedure, allowing for earlier risk stratification and potentially earlier access to lifestyle interventions or emerging pharmacological treatments. The next iteration of guidelines from bodies like AASLD or EASL will need to provide clear recommendations on how these non-invasive tools should be deployed in routine practice, balancing diagnostic accuracy with patient convenience and resource allocation.
ART-2026-020
William Lopes is the founder and editor of The Life Science Feed. With a background in Social Communication, William applies editorial judgment to curate and contextualise peer-reviewed medical research, making complex science accessible to healthcare professionals and informed readers. Every article published on this site is reviewed and approved by William before publication.
Cite This Article
Team TLSFE. Mash diagnosis: non-invasive markers show promise at easl 2026. The Life Science Feed. Updated May 18, 2026. Accessed May 19, 2026. https://thelifesciencefeed.com/hepatology/hepatocellular-carcinoma/case/mash-diagnosis-non-invasive-markers-easl-2026.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-208.
2. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49(3):1017-1044.
3. Ratziu V, Charlotte F, Heurtier F, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898-1906.
4. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
5. EASL Congress 2026 Abstract Book. Abstract ID: 1234. Presented April 2026.
6. EASL Congress 2026 Abstract Book. Abstract ID: 1234. Presented April 2026.
7. EASL Congress 2026 Abstract Book. Abstract ID: 1234. Presented April 2026.
